Document is current
Any future updates will be listed below
-
Authors
Ang, Koon Hwee https://orcid.org/0000-0002-0321-1992
Thura, Min https://orcid.org/0000-0002-0462-9020
Tan, Queenie Shu Woon
Gupta, Abhishek
Kuan, Kam Yew https://orcid.org/0009-0005-0897-8366
Li, Jie https://orcid.org/0000-0001-6404-1432
Chia, Pei Ling https://orcid.org/0000-0002-1656-4770
Qiu, Beiying https://orcid.org/0009-0003-2662-2959
Hong, Jimmy Ming https://orcid.org/0000-0001-6666-0763
Guo, Ke
Wang, Xiaomeng https://orcid.org/0000-0002-1036-2764
Su, Xinyi https://orcid.org/0000-0002-1480-6713
- License Information
-
More Information
Article History
Received: 28 February 2024
Accepted: 8 May 2025
First Online: 23 May 2025
Competing interests
: Q.Z. is the Founder, K.H.A. is the Chief Operating Officer (recent J.A.), M.T. is the Chief Medical Officer (recent J.A.), and K.K.Y is the Clinical Research Coordinator (recent J.A.) of Intra-ImmuSG Pte Ltd., an Agency for Science, Technology and Research (A*STAR) spin-off company granted licensing rights for the PRL3-zumab IP portfolio. The other authors declare no competing interests. J.A.: Joint Appointment.
